News Releases

April 29, 2020
Zurich-Schlieren, Switzerland, April 29, 2020. At today’s Annual General Meeting of Molecular Partners AG (SIX: MOLN), a clinical-stage biotech company that is developing a new class of custom-built protein therapeutics known as DARPin® therapeutics, the shareholders of the company approved all
Displaying 111 - 120 of 194
* These releases may contain price sensitive information